Bayer Anchors US Pharma Ambitions With $2.2 Billion Ohio Plant as Pipeline and Financing Moves Accelerate

Bayer earmarks $2.2 billion for its first North American pharma production site in Ohio, as US tariffs reshape drugmakers' manufacturing plans.

Bayer is betting that manufacturing on American soil will shield its most important market from shifting trade winds. The Leverkusen-based group has earmarked $2.2 billion for a new pharmaceutical production site in New Albany, Ohio — its first facility of this kind in North America — designed to churn out active pharmaceutical ingredients alongside finished medicines targeting cancer, heart disease and kidney conditions.

The project will be built in stages. The first phase is slated to come online in 2031, with a second following in 2034, and roughly 600 skilled positions are planned once operations are running. Ohio's governor framed the outlay as a record German investment in the state and the largest international healthcare-sector project it has ever attracted. According to DPA, Bayer has already poured more than $7 billion into US pharmaceutical research, development and production over the past five years.

Tariff Pressure Reshapes the Calculus

Washington's protectionist turn explains much of the urgency. President Donald Trump has imposed tariffs on certain patented imported medicines and intends to add levies on generic imports from 2028. He has credited such measures with drawing more than $600 billion in pharma investment into the country. At the same time, his administration is pressing for lower domestic drug prices while pushing for higher prices abroad — a combination that makes local manufacturing capacity a strategic necessity rather than a mere cost consideration for international drugmakers.

A New Medical Chief and a Rare-Disease Boost

Operational changes are unfolding in parallel with the construction plans. On Thursday, Bayer named Dr. Christoph Koenen as Chief Medical Officer of its pharmaceuticals division, effective October 1. Koenen will retain his existing roles leading clinical development and operations, consolidating the oversight of the company's drug pipeline under a single executive.

Regulatory momentum has also picked up. BlueRock Therapeutics, a Bayer subsidiary, reported Wednesday that both the US Food and Drug Administration and the European Medicines Agency granted Orphan Drug status to Lemiretprocel, also known as OpCT-001, a candidate therapy for certain inherited retinal diseases. The designation is intended to speed development of treatments for rare conditions and provides procedural support during clinical trials.

Divestment and Refinancing Round Out the Agenda

Portfolio housekeeping continues alongside the pipeline work. On September 21, Bayer agreed to sell rights to its cancer drug Stivarga to pharmaceutical company Grünenthal for up to EUR 375 million, with the deal expected to close in late 2026 or early 2027. Two days later, management moved to shore up its financial footing, placing EUR 2 billion in hybrid bonds across two separate tranches. The total outstanding volume of these subordinated notes now stands at EUR 6.55 billion.

Shares Give Back Recent Gains

The stock has softened over the past several sessions. Bayer closed Friday at EUR 45.02, a decline of 10 percent over seven days, though the shares remain up 22 percent since the start of the year. How durable that advance proves to be will hinge largely on whether the long-term US buildout can absorb future tariff-related pressure.